Rapid immunochromatographic test for detection of anti-factor XIII A subunit antibodies can diagnose 90 % of cases with autoimmune haemorrhaphilia XIII/13

Summary

Autoimmune haemorrhaphilia XIII/13 (AH13) is an acquired lifethreatening bleeding disorder due to anti-factor XIII (FXIII) autoantibodies (auto-Abs). AH13 patients may die of haemorrhage without correct diagnosis and proper treatment because of lack of awareness and the absence of rapid easy-to-use tests specific for this disease. Currently, the definitive diagnosis is established by cumbersome and time-consuming laboratory tests such as dot-blot assays and enzymelinked immunosorbent assays (ELISA), and therefore these tests are generally not carried out. To save AH13 patients’ lives, there is an urgent necessity for developing a rapid test for FXIII auto-Abs. We first generated and characterised mouse monoclonal antibodies (mAb) against human FXIII A subunit (FXIII-A), and then developed a rapid immunochromatographic test (ICT) for detection of anti-FXIII-A auto- Abs using one mAb with a dissociation constant of 9.3 × 10^-11 M. The auto-Ab-FXIII-A complex was captured by the mAb on a nitrocellulose membrane and visualised by Au-conjugated anti-human IgG Ab. Mixing with healthy control plasma improved the detection of auto-Abs in patients having extremely low levels of FXIII-A. The specificity and sensitivity of the ICT were 87% and 94%, respectively. We also detected auto-Abs against activated FXIII (FXIIIa) in three patients by pre-converting FXIII to FXIIIa by thrombin treatment. ICT values were significantly inversely correlated with FXIII activity levels, indicating an association between the quantity of anti-FXIII autoantibodies and AH13. This reliable rapid ICT assay can be applied to a point-of-care test to detect anti-FXIII-A auto-Abs, and will contribute to early diagnosis and treatment of AH13.

Keywords

Acquired coagulation disorders - autoantibodies - autoimmune diseases - factor XIII / transglutaminases - diagnosis management

• References

• 1 Komáromi I, Bagoly Z, Muszbek L. Factor XIII: novel structural and functional aspects. J Thromb Haemost 2011; 09: 9-20.
• 2 Ichinose A. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control. Int J Hematol 2012; 95: 362-370.
• 3 Schroeder V, Kohler HP. Factor XIII deficiency: an update. Semin Thromb Hemost 2013; 39: 632-641.
• 4 Egbring R, Kröniger A, Seitz R. Factor XIII deficiency: pathogenic mechanisms and clinical significance. Semin Thromb Hemost 1996; 22: 419-425.
• 5 Ichinose A. Haemorrhagic acquired factor XIII (13) deficiency and acquired haemorrhaphilia 13 revisited. Semin Thromb Hemost 2011; 37: 382-388.
• 6 Sugiyama H, Uesugi H, Suzuki S. et al. Aggressive fatal case of autoimmune haemorrhaphilia resulting from anti-Factor XIII antibodies. Blood Coagul Fibrinolysis 2013; 24: 85-89.
• 7 Lorand L. Haemorrhagic disorders of fibrin stabilisation. In: Ogston D, Bennett B (eds). Hemostasis: Biochemistry, Physiology and Pathology. John Wiley & Sons Ltd; 1977. pp. 405-423.
• 8 Lorand L, Losowsky MS, Miloszewski KJ. Human factor XIII: fibrin-stabilizing factor. Prog Hemost Thromb 1980; 05: 245-290.
• 9 Lukacova D, Matsueda GR, Haber E. et al. Inhibition of factor XIII activation by an anti-peptide monoclonal antibody. Biochemistry 1991; 30: 10164-10170.
• 10 Lorand L, Velasco PT, Murthy SN. et al. Autoimmune antibody in a haemorrhagic patient interacts with thrombin-activated factor XIII in a unique manner. Blood 1999; 93: 909-917.
• 11 Ajzner E, Schlammadinger A, Kerényi A. et al. Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency. Blood 2009; 113: 723-725.
• 12 Kohler HP, Ichinose A, Seitz R. et al. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011; 09: 1404-1406.
• 13 Lorand L. Acquired inhibitors of fibrin stabilisation: a class of haemorrhagic disorders of diverse origins. In: Green D (ed) Anticoagulants, Physiologic, Pathologic and Pharmacologic. CRC Press; 1994. pp. 169-191.
• 14 Ichinose A, Souri M. Japanese collaborative research group on “Acquired haemorrha-philia due to factor XIII deficiency”. As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan. Thromb Haemost 2011; 105: 925-927.
• 15 Ichinose A, Souri M. Reduced difference of α₂-plasmin inhibitor levels between plasma and serum in patients with severe factor XIII deficiency, including autoimmune haemorrhaphilia due to anti-factor XIII antibodies. Int J Hematol 2012; 95: 47-50.
• 16 Cini M, Legnani C, Cavallaroni K. et al. A new rapid bedside assay for D-dimer measurement (Simplify D-dimer) in the diagnostic work-up for deep vein thrombosis. J Thromb Haemost 2003; 01: 2681-2683.
• 17 Neale D, Tovey C, Vali A. et al. Evaluation of the Simplify D-dimer assay as a screening test for the diagnosis of deep vein thrombosis in an emergency department. Emerg Med J 2004; 21: 663-666.
• 18 Warrener L, Slibinskas R, Brown D. et al. Development and evaluation of a rapid immunochromatographic test for mumps-specific IgM in oral fluid specimens and use as a matrix for preserving viral nucleic acid for RT-PCR. J Med Virol 2010; 82: 485-493.
• 19 Handali S, Klarman M, Gaspard AN. et al. Development and evaluation of a magnetic immunochromatographic test to detect Taenia solium, which causes taeniasis and neurocysticercosis in humans. Clin Vaccine Immunol 2010; 17: 631-637.
• 20 Souri M, Kaetsu H, Ichinose A. Sushi domains in the B subunit of factor XIII responsible for oligomer assembly. Biochemistry 2008; 47: 8656-8664.
• 21 Souri M, Biswas A, Misawa M. et al. Severe congenital factor XIII deficiency caused by novel W187X and G273V mutations in the F13A gene; diagnosis and classification according to the ISTH/SSC guidelines. Hemophilia 2014; 20: 255-262.
• 22 Hoylaerts MF, Bollen A, De Broe ME. The application of enzyme kinetics to the determination of dissociation constants for antigen-antibody interactions in solution. J Immunol Methods 1990; 126: 253-261.
• 23 Wada H, Souri M, Matsumoto R. et al. Alloantibodies against the B subunit of plasma factor XIII developed in its congenital deficiency. Thromb Haemost 2013; 109: 661-668.
• 24 Nagaraj N, Kulak NA, Cox J. et al. System-wide perturbation analysis with nearly complete coverage of the yeast proteome by single-shot ultra HPLC runs on a bench top orbitrap. Mol Cell Proteomics 2012; 11: 1-11.
• 25 Olsen JV, Macek B, Lange O. et al. Higher-energy C-trap dissociation for peptide modification analysis. Nat Methods 2007; 04: 709-712.
• 26 Cohen JA. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960; 20: 37-46.
• 27 Swets JA. Measuring the accuracy of diagnostic systems. Science 1988; 240: 1285-1293.